
Improving Outcomes for Individuals With Serious Mental Illness and Diabetes
Diabetes MellitusBipolar Disorder3 moreThis project tests a model for improving illness self-management among persons who have both serious mental illness and diabetes and will be performed within a primary care setting at a safety net hospital system. The information gained from the randomized trial will be supplemented with reports from participants about their experiences of trying to improve illness self-management. Improvements in self-management should result in a reduction of psychiatric symptoms and improvements in functioning and physical health.

Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl
SchizophreniaSchizoaffective Disorder1 moreThe objective of this study is to evaluate the effect of calorie and fat content on the pharmacokinetics of Lurasidone HCl in subjects with schizophrenia, schizoaffective disorder, or schizophreniform disorder.

Effects of Delta-9-THC and Iomazenil in Healthy Humans
SchizophreniaMental Disorders1 moreThe study aims to examine the combined effects of delta-9-tetrahydrocannabinol (∆-9-THC or THC) and iomazenil on thinking, perception, mood, memory, attention, and electrical activity of the brain (EEG). THC is the active ingredient of marijuana, cannabis, "ganja", or "pot". Iomazenil is a drug that works opposite to drugs like valium. The purpose of this study is to determine whether the administration of iomazenil will alter the effects of THC.

Outcome Evaluation of Solutions for Wellness and Team Solutions Program in Patients With Severe...
SchizophreniaSchizoaffective Disorder1 moreObesity is increasing at an alarming rate in patients with schizophrenia, possibly in association with the increased use of atypical antipsychotics. In order to address the weight and metabolic syndrome issues, Manhattan Psychiatric Center (MPC) has implemented the Solutions for Wellness and Team Solutions Program. This program is designed to create a supportive, educational and monitoring environment to stabilize both the psychiatric and medical conditions and to prepare patients for independent management of their psychiatric and physical health condition in the community.

Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia
SchizophreniaSchizoaffective Disorder2 morePrimary Objective: To test the effect of pramlintide on body weight in clozapine- and olanzapine-induced weight gain in persons with schizophrenia who are currently taking either drug; measures of the metabolic syndrome will be evaluated as well.

Training-induced Cerebral Reorganization in Schizophrenia
SchizophreniaThe purpose of this study is to reveal the effects of computer-aided cognitive-auditory training on cerebral reorganization in schizophrenia.

Study Comparing Bioavailability of Oral Formulations of Vabicaserin
SchizophreniaThe purpose of this study is to determine the absorption rate of four oral formulations of vabicaserin.

Escitalopram in Schizophrenia in OCD- Open Label Study
SchizophreniaSSRI's has been demonstrated to be partially effective in schizophrenia and OCD. We therefore suggest that Escitalopram up to 20 mg /d in those patients could be effective in reducing obsessive compulsive symptomatology

Rehabilitative Training for Older People With Schizophrenia
SchizophreniaThis study will evaluate the effectiveness of a rehabilitation program called Functional Adaptation Skills Training (FAST) in treating older patients with schizophrenia.

Augmenting Zyprexa With Naltrexone to Ameliorate Metabolic Side-Effects
SchizophreniaPsychotic DisordersThe main purpose of this study is to determine whether the opioid antagonist naltrexone is helpful in ameliorating the weight gain and other adverse metabolic side effects experienced by schizophrenic patients taking the second generation antipsychotic (SGA) Zyprexa. Schizophrenics may have an altered/enhanced endogenous opioidergic drive, and because of this, normally painful stimuli will be sensed as less painful in schizophrenics vs. healthy controls. A secondary hypothesis for this study is that naltrexone augmentation of Zyprexa will normalize subjective pain ratings. Our tertiary objective is to examine the safety and tolerability of naltrexone in Zyprexa-treated patients with schizophrenia.